Immunome
IMNM
31 hedge funds and large institutions have $64.6M invested in Immunome in 2021 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 3 closing their positions.
232% more capital invested
Capital invested by funds: $19.5M → $64.6M (+$45.2M)
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
24% more funds holding
Funds holding: 25 → 31 (+6)
1.2% less ownership
Funds ownership: 19.11% → 17.91% (-1.2%)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.83M |
| 2 |
BlackRock
New York
|
+$1.02M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$849K |
| 4 |
State Street
Boston,
Massachusetts
|
+$809K |
| 5 |
BIM
Baldwin Investment Management
West Conshohocken,
Pennsylvania
|
+$631K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.83M |
| 2 |
PCM
Prentice Capital Management
Greenwich,
Connecticut
|
-$2.1M |
| 3 |
Millennium Management
New York
|
-$657K |
| 4 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$645K |
| 5 |
KC
Kepos Capital
New York
|
-$645K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIP
26
Ameritas Investment Partners
Lincoln,
Nebraska
| $6K | – | – | – |
|
27
Citigroup
New York
| $5K | -$2.36K | -95 | -40% |
|
28
Morgan Stanley
New York
| $4K | -$52.9K | -2,128 | -95% |
|
29
Bank of Montreal
Toronto,
Ontario, Canada
| $2K | -$8.2K | -330 | -85% |
|
|
AIG
30
American International Group
New York
| $41 | +$75 | +3 | +0.2% |
|
|
31
Millennium Management
New York
| – | -$657K | -67,863 | Closed |
|
|
GPCM
32
Granite Point Capital Management
Boston,
Massachusetts
| – | -$645K | -66,666 | Closed |
|
|
KC
33
Kepos Capital
New York
| – | -$645K | -66,666 | Closed |
|
34
Rockefeller Capital Management
New York
| – | +$497 | +20 | New |
|
IMNM Hedge Fund Activity: Q1 2021 in Review
31 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q1 2021, worth a combined $64.6M — up 232% from $19.5M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new IMNM positions and 3 closed out — a net gain of 6 holders — while 8 added to existing stakes and 12 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $3.83M. The largest seller was Fidelity Investments, cutting an estimated $2.83M.
- 31 institutional investors held Immunome (IMNM) as of Q1 2021, up from 25 in Q4 2020.
- Funds reported $64.6M of Immunome stock for Q1 2021, up 232% quarter-over-quarter.
- 9 funds opened new Immunome positions in Q1 2021 and 3 closed out, a net change of +6 holders.
- The largest Immunome buyer in Q1 2021 was Vanguard Group, an estimated $3.83M added.
- The largest Immunome seller in Q1 2021 was Fidelity Investments, an estimated $2.83M sold.
Based on aggregated 13F filings for Q1 2021.